Sulfisoxazole is a sulfonamide antibiotic used with other antibiotics to prevent and treat a variety of bacterial infections. A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
- Mechanism
- Curator reviewed
Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
- Primary indication
- For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.Curator reviewed · 1 structured indication
- Formula / weight
- C11H13N3O3S · 267.304 g/mol (avg)
- First approval
- Canada, 1997
- Also known as
- Sulfadimethylisoxazole · Sulfafurazol · Sulfafurazole · Sulfaisoxazole · Sulfasoxazole
Resolves to
NHUHCSRWZMLRLA-UHFFFAOYSA-NSMILESCC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1CWhat you can answer from here — as of October 01, 2026
Which drugs share a target with Sulfisoxazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account